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m’907147 Relatlonof MaximalOxygenUptaketo LeftVentricularFunctionin PatientswithDilated
Cardiomyopathy
R kpu-Bula, A. Roben, M. De Kock,J. Melin,A.-M. D’Hondt,
J.-L. Vanoverachelde.Urrivereityof Louvairf, Brusae/s, fie/gium
Reduced exercise capacity (EC) is a cardinal symptomin patients(pts)
with dilated cardiomyopathy(DCM) and chroniccongestiveheart failure.
Previousstudieshaveshownthatthe severityof reductioninEC inthesepts
correlatedpoorlywiththe degreeof leftventricular(LV)systo[icdysfunction.
As diastolicdysfunctionis commonamongpts witha DCM, we evaluated
the possibilitythat differencesin diastolicLV functioncontributedto their
variableEC. Accordingly, we studied 26 consecutive pts (61 * 12 yrs) with
a DCM (LV end-diastolicdimension>60 mm, shorteningfraction <25’%.)
in NYHA functionalclass I-HI. Their mean ejectionfraction(EF) was 30 +
10%. AIIptswerein sinus rhythm and off fl:blockers at the time of the study.
EC was measured as peak oxygen uptake (VOZ)during a symptom-limited
treadmill exercise (modified Bruce protocol). LV intemaldimensions(m-mode
echo),EF(radionuclideventriculography)anddiastolicfillingparameters(PW
Doppler)were measuredat reet in every pte immediatelybeforeexercise.
Peak VQ rangad from 12t036mUk@min (mean21 + 6)andcorrelatsdwith
the followingparameters:the ratioof earfyto latetransmittalfilling velocities
(E/A ratio, r= O.64,p < 0.001), peak early filling velocity (r= O.77,p < 0.001),
isovolumic relaxation period (r= 0.75, p < 0.001), deceleration time (r= 0.70,
p < 0.001), atrial filling fraction (r= 0.66, p -= 0.001), LV EF (r= 0.39, p =
0.05), meanVcf (r= 0.14, p = ns)and,LVend-diastolicdimensions(r = 0.10,
p = nS).Our data thus indicatethat indicesof diastolicretherthan syetolic
functioncorrelatewithexercisecapacityin ptswithDCM. Thissuggeststhat
LVdiastolicdysfunctionmay playa role in limitingEC inthese pts.
m907148 Characterizationof DifferentTimeCoureeaof Left
andRightVentricularRacoveryAfterLung
Transplantation
C.H. Lorenz,J.E. Loyal,S.S. Klein,V.L. Morgan,E.S. Walker,W.H. Frist,
T.P.Graham,Jr. Barnes-Jewish Hospital, St. Louis, MO, USA, Vandetiilt
Univem”fyMedical Centec Nashville, TN, USA
Cine MRI was used to determine the time-course of changes in ventricular
mase and function after lung transplantation (LT).The studygroupsincluded
65 healthysubjects, 44 studies on 43 patients ,withpulmonary hypertension
beingevaluatedfor LT.and 25 studies on 11 patients following lung trans-
plantation [earfy: -=6mos post-LT,intermediate: 6-16 mos post-LT,and late:
>18 months post-LT]. RV and LV mass,volume and functional parameters
were determined from the tomographic MRI datesets (maasandvolumenor-
malized to body surface area). RV ejectionfraction(RVEF) normalizedinthe
early poat-LTperiod. RV end-diastolicvolumedecreased to below normal
levels early and remained low even in the late studies. RV mass regressed,
but remainedelevated comparedto control.LV mass was belownormalin
the pre-LTgroup,but increasedto slightlyabove normalearly post-LTand
returnedto normal by late post-LT.LVEF normalizedby the intermediate
periodwhileLVEDVnormalizedinthe earlypost-LTperiod.Inaummary,both
functionaland structuralrecoveryoccurs in the early to intermediate peat-LT
perfod forfhe LV. In the RV,structural recovery lags functional recovery,and
RVstruofure isnot Completelynormali.zedby 18monthspost-transplantation.
We speculate that the mechanisms resfxrnsible for these disparate effects
reflect rapid adjuatmenta to preload changes in the LV and more protracted
adjustment to afterload changes in the RV.
Control Pre-LT Earlypost ht. post-LT Latepost-LT
RVEF 60.8k 0.8 45.4k 2.4” 55.8*4.3 64.5l2.2* 59.1+2.4
RVEDVIB6A 74.1+ 1.5 89.8+ 6.7” 66.0+ 8.1 50.9* 3.9* 62.7*7.9*
RVmaaaJB6A 26.1+ 0.5 48.7+ 3.S” 45.0+ 3.9* 30.1+ 2.3” 35.4*4.6*
LVEF 86.8+ 0.6 61.1+ 2.2* 55.8+4.1* 64.1+ 2.1 62.0+ 3.9
LVEDWSSA 65.5+ 1.3 45.S+2.3* 65.2+ 9.1 53.4+4,0” 5S.94C5.2*
LV meas/BSA 87.3 & 1.4 76.1 k 3.4* 95.1 i 5.7* 80.2 k 2.5* S6.S*6.2
“significantlydifferentfrom controlat p <0.05 level
1907-161] hlha,edNitricOxideiSa~*9stiveRi9ht
Ventricular(RV)Inotropein PrimaryPulmonary
Hypertension
P.J.Counihan,J. Gorcsan,Ill, L. Firestone,W.A. Mandarino,W.E. Katz,
M.D. Feldman,S. Murali.Universifyof Pittsburgh, Pitfsbugfr, PA, USA
Inhalednitricoxide (NO) reducespulmonatypressuresin patientswithpri-
marypulmonaryhypertension(PPH). This effect may be due to pulmonary
vaaodilatation. More recently NO has been shown to have direct negative
inotropic effects. Accordingly we hypothesised that the hemodynamic effects
of NO are due in part toa negative RV inotropiceffect.Methods: RV pressure-
area kJops were recorded at baseline and during inhalation of NO 60 ppm,
using transthotacic echo and high-fidelity pressure during WC occlusion in
7 patients (age 42 & 8 yrs) with PPH. RV end-systolic pressure (RVESP),
cardiac output and peak +dP/dt fell significantly with NO. Emax tended to
decrease with a marked right-ward shift in pressure-area loops in W pta
implying a negative inotropic effect (fig).
Baseline No P
RVESP 85+ 19 76~ 17 0.05
PCWP 7*3 9+5 0.10
co 4.3 i 1,4 3.4 * 0.7 0:05
RV + dP/dt 59S & 165 512 & 126 0.05
RVEmax 15.0 +9,0 t2.1 + 6.0 0.10
RVha (on+)
Conclusion: Inhaled NO reduces RV pressurea in PPH which is mediated
in part by a negative inotropic effect on RV performance.
D ,;bro~;907162 DlaatobcDysfunctionin PatientswithCystic
TM. Koelling, L.C. Ginns, K.-T. Khaw, D.M. Systrom, G.W. Dac, T.G. Di
Salvo, M.J. Semigran. Massachusetts General Hospital and Harvard
Medical School, Boaton, MA, USA
Although myocardial fibrosis has been described in autopsy epecimens of
patients with cystic fibrosis (CF) with acute left ventricular failure, no clear
association has been identified between CFand aeymptomatic Ieftventricular
dysfunction. To asseas the possibility of cardiac dysfunction occurring in
CF, we studied 40 patients with advanced CF under evaluation for lung
transplantation with firat-pass radionuclide ventriculography and compared
them to 18 normal controls (NL) and 9 patients with advanced bronchiectaeis
(BR) (ages, 29 + 8,37 + 12”, and 33 + 7 yeara, reapaciively (mean + SD).
‘ p <0.05 vs CF). RVEF for CF (0.34 + 0.07) and BR (0.35 + 0.06) was
lower than NL (0.44+ 0.068). Indicea of left ventricular aystolic and diastolic
fundion are shown in the Table below.
CF EIR NI
LVEF 0.62 + 0.08 0.63 +0.0S 0,62 + 0,06
AtrialFilling‘A 3s * 1s 21 k4* 25 h 12”
17meto Peak Filling/RR 0.25 + 0.07 0.21 +0.0s 0,22 +0.06
Fillinaat 50°A Ltiast.de 54* 13 66 *4* 69* 14*
Conclusions: 1) Patients with advanced lung disease from cystic fibrosia
demonstrate diastolic dysfunction when compared to normal controls and
to patients with bronchiectasis. 2) Patients with long 8tanding cystic fibrosis
may be at risk of congestive heart failure due to impaired left ventricular
relaxation caused by myocardial fibrosis,
907-163 EnhancsdDelineationof PericardialDieeaeesby
Three-DimensionalEchocardiography
T.-L. Hsu, S.J. Ho, J.-J. Wang, S.-P.Wang, M.-S. Chang, R. Kasliwal,
N. Pandian. Division of Cardiolog~ Veterans General Hoapital-Taipei,
Taiwan,Republic of China, TuftaNew England Medical Cente< Boaton, USA
Intrapericerdial abnormalities such as effusion, fibrin, hematoma, tumor and
fat pad could be easily identified by 2-dimensional achocardiography (2DE).
However, the usefulness of voxel-based 3-dimensional echocardiography
(3DE) has not been examined in evaluating of pericardial disease (PD). The
purpose of this study was to assess the diagnostic value of 3DE in the
delineation of intra-pericardial pathologies. Multilane transesophageal 2DE
was performed in 21 patients (pts) including Ioculatad pericerdial effusion
(PE) in 6 pts and circumferential PE in 5 pts, effusive-constriction in 2 pts,
constrictive pericarditis in 2 pts, pericardial cyst inone pt, primary paricardiaf
tumorin one pt and metaatetic tumor in 2 pts. Sequential 2D images were ac-
quirsd and reconstructedby volume rendering. Resu/ts:From the3Ddataset,
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The size, location and extent of fluid distribution, perieerdial wall thickness
and intraperieardlal abnormalities Couldbe delineated using anyplane echo. ‘
Loeulatad PE volume could be determined in all 8 pts. The pericardial wall
thickness eouid be measured and correlated well with the surgieel specimen
in 2 pts. The epicardial surface morphology, dynamic cardiac motion and
pathology Couldbe viaualizad in patients with moderately to large amount of
PE. The extent of Cardiaccompression could be assessed. Conclusion: 3DE
provides additional diagnostic information in assessing the spatial orienta-
tion of PD and could beviaualized the epicardiac motion and intra-pericardial
pathology in effusive pts.
/907-164]Ma~na,c~~~~n~n~~,~*ging~i~~~~g ingin
Constrictive Pericerditis
G. Holmvang, R.E. Dinsmore. Maasschusetts General Hospital, Boston,
MA, USA, Boston Heart Foundation, Cambridge, MA, USA
Magnetic Resonance Imaging (MRI) is offen helpful for establishing the
diagnosis of conatrietive perieerditis in patients with constricfiveh’estrietive
hemodynamic findings, by demonstrating abnormal pericardial thickening.
However, constriction may exist in the presence of only mild pericardial
thickening (c4 mm), and mild thickening can be difficult to differentiate from
a minor increase in perieardial fluid. MRI tharefore remains equivocal in some
0ss0s.
To help identify abnormal perieerdial function, a simple MR imaging
scheme was implemented in which magnetic tag lines (slices orthogonal
to the desired imaging plane) are prescribed graphically at right angles to the
perieardial surface and depositad at end-diastole. Normal pericerdial slid-
ing motion appears as a break in the tag line at the pericardial interfaca in
late aystolic images. Perieerdial adheaion is identified by absence of such
discontinuity in spite of deformation of the tag across the myocardium.
The above imaging protocol wee applied in 23 consecutive patients eval-
uated for possible constrictive pericarcfitis.Adhesion of pericardial surfacas
was identified in all 10 patients who had a final diagnosis of constriction, and
the distribution of adhesions was verified intraoperatively in 8 patients who
underwent periesrdieetomy. However, extensive adhesion was aleo found in
two patients who did not have constriction, including on ra-imaging following
perioardieotomy.
Weconcludethat MRI tagging allows identification of the perieerdialadhe-
sion associated with constriction, and is a helpful new tool for demonstrating
abnormal function where morphological changes may be mild, However,
confirmation of constriction alao requires that constrictive physiology must
be demonstrated. The method can beimplementad on a commercial scanner
without need for apeoialized pulse sequences.
D907165 Calcific Constrictive Pericarditis: A PassePhenomenon?
L.H. Ling, J.K. Oh, J.F. Breen, J.B. Seward, A.J. Tajik. Mayo C/inicand
Mayo Foundation, Rochestefi MN, USA
With the declina in tuberculosis, calcific constrictive pericarditis (CCP) is be-
Iievedtobe uncommon in the United States. We reviewed a 10-yrexparience
of 135 patients with surgically proven constrictive periearditis to determine
the incidence of CCP and its cliniesi correlates in the current era. Pericardial
calcification was present on chest x-ray in Mpts (25%, group i) and absent
in 101 oases (group H).
GroupI GroupII P value
Males 30(88%) 73(72%) 0.058
Ags
Symptomduration
NYHAclass111-iV
‘ldlopSthiC’cause
Post-surgicalcauae
Infectivecause
Atrialarrhythmia
Psrioardialknock
Perieerdialrub
Lsftatrial size
57* 17yr
33.2 mo
19 (564/0)
24 (71”/6)
o (o%)
o (o”A)
14 (41”/4)
22 (65%)
2 (8%)
50 h 9 mm
58 i 16 yr
8.4 mo
74 (75%)
21 (21%)
23 (23°/6)
4 (4%)
9 (9%)
41 (41”/6)
20(20%)
43k 8mm
ns
<00001
ns
0,001
0.004
::01
0.015
0.057
0.0007
Conclusions: 1) Perioardial calcification on chest x-ray is still raiatively
common, and remaina an important clue to the diagnoais of constriction,
2) CCP ia positively correlated with diseasa chronicity, a perioerdial knock,
atrial enlargement and atrial amhythmias, 3) The etiology of CCP is usuaily
indeterminate, even after an exhaustive saareh for tuberculoua and fungal
dieease.
[907-1661 Recurrent pericarditisand Colchicine:10-Yeareof
Experience
Y.Adler, J, Guindo, A. Rodriguez, Y, Shoenfeld, M. Ravid, M. de-Miguel,
M. Subirana, J. Shemesh, Y. Finkelstein, T. Bayes, J. Amir, G. Zandman,
D. Martinez, P.Langevitz, D. Zemer, M. Ehrenfeld, N. Krivoy, S. Sclarowaky,
A. Bay6s-de-Luna. Rabin Medical Centec Israel, Hospital de Sant Pau,
Barcelona, Spain
Recurrence is one of the major complications of pericarditia. Its treatment is
often difficult and corticosteroids, immunosupressive drugs or surgery may
be necessary. We conducted an international, multicenter study of patients
(pts) with recurrent pericarditis treated with colchicine (C). We included 41
pts (27 men; mean age 38.9 + 17.8 years). Pericarditis was idiopathic
in 28 pts and secondaty in 13. Before C pts received aspirin or NSAID
(n = 37), cortocoids (n = 27) and paricardiocentesis (n = 7) and a total
of 155 recurrences were noted (mean 3.7 & 2.8) with a median interval
between crises of 2.0 months (range 0.5-19). Pts were treatad with C (0.5-2
m@day)with a median duration of 13 months (range 3-128). For stetietieal
analysis, we mnducted a paired comparison design (Student’s t teat). During
the 939 months of C treatment only 8/41 pts presented new recurrences
(14.6%). C was dismntinued in 31 pte and a new relapae occurred in 13
eaaes (41.9%). Recurrences were generally minor and effectively controlled
with the reinitiation of C or adjuating its dosis. During a tofei follow-up of
2021 months 23/41 pts (56.1%) did not experienced new recurrences. The
differences between the symptom-free periods before and after treatment
with C (3.2 * 2.8 vs 47.9 + 35.2 months) are statistically significant (p c
0.0001). Cone/usiorr:Colchicine is an effectivaand safe drug forthe long-term
prevention of pericarditis.
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1908-167] Long-term inhibitorYEffedSOf EndO~enOuS
Nstriuretic Peptide Activities on Cardiorensl and
Neurohumorel fectors in Heart Fsilure
D. Fukai, A. Wada, T. Tsutamoto, Y. Maeda, M. Ohnishi, M. Kinoshita. Shiga
Univeraify of Medica/ Science, Otsu, Japan
The changes that defects in natriuretic peptides (NPs) can provoke in hemo-
dynamic, renal and neurohumoral factors in a pathological condition such as
heart failure (HF) have not been reported. To examine the effects of long-
term inhibition of NPsaetivities, we administrated an antagonist forguanylate
cyclase coupled NP receptors, HS-142-1 (HS), for 24 hours (1 mg/kg/hr) to
anesthetized dogs with early-stage HF induced by rapid ventricular pacing
(270 ppm, 8 days). In this experimentally produced HF, plasma ANP levels
were significantly increased from 51 to 240 (p < 0.01), but the plasma renin
activity (PRA) and plasma aldosterone levels were not higher than those in
the normal controls (4.15 vs 5.04, 70 vs 82, respectively, N.S).
HS (n = 5) Vehicle (n= 5)
Baseline 4 hrs 24 hrs Baseline 4 hra 24 hra
ANP (pg/ml) 240 314++ 3os# 256 238 242
Plasma cGMP 33.s 13.0” 12.2* 35.0 24,0 37.0
(pmolJml)
MAP (mmHg) 111,0 114.5 116.0 109.6 110.0 10s.5
PCWP (mmHg) 13.3 15.4# 16,24 13.4 13.7 13.4
U-V (m!fhr) 24.2 11.9$ 20.3t 20.3 19.4 19.7
PRA (ng/ml/hr) 5.04 7.36# 4.66t 5.28 5,73 4.31
Aldoaterone(pg/ml) 82 450# 260%t 143 114 114
‘P <0.05, *P <0.01 vs Baseline, tP <0.05 vs 4 hours,MAP; mean arterial pressure,
PCWP; pulmonarycapillaIywedge preaaure, U-V; urineflow rate.
HS significantly suppressed plasma cGMP ievels throughout the exper-
iment. PCWP but not MAP was elevated for 24 hours continuously. U-V
decreased, and PRA and plasma aldosterone ievel increased only aftar
4 hours of HS infusion. Unexpectedly, these parameters tended to return
to baseline values after 24 hours of infusion. EndWenqus NPs regulated
vascular tone and urine excretion, and suppressed the activation of the
renin-angiotensin system in the early-stage HF, before apparent elevation of
PRA and plasma aldosterone. However, long-term inhibition of NPs did not
cause the progressive exacerbation of volume retention or the activation of
the ranin-angiotensin system in dogs with HF.
